Individuals with cancer expressed a preference for early and frequent provider-initiated discussions about financial toxicity, according to study findings.Researchers sent anonymous surveys to 5,774 people who subscribed by email to the Pink Fund, a nonprofit charity that offers financial assistance to people undergoing treatment for breast cancer.
Abdul Rafeh Naqash, MD, discusses the potential role for abequolixron plus docetaxel in recurrent advanced non–small cell lung cancer.
SAN DIEGO — Insurers rejected one-third of new prescriptions for specialty oral anticancer medications ordered for patients with blood cancers, according to retrospective data presented…
Looking back on the accomplishments of recent past presidents of CHEST, John A. Howington, MD, MBA, FCCP, hopes to “continue the upward momentum” in his…
Azenosertib monotherapy showed a 34.9% overall response rate in heavily pretreated, cyclin E1–positive, platinum-resistant ovarian cancer, with a median duration of response of 5.5 months.
WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
An abstract is unavailable.
Discover the role of ctDNA in managing colorectal cancer, from guiding treatment decisions to assessing the risk of overtreatment.
Guillermo Garcia-Manero, MD, discusses the developmental progress of emavusertib for the treatment of acute myeloid leukemia and myelodysplastic syndromes.
